Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TherapeuticsMD Inc    TXMD

THERAPEUTICSMD INC (TXMD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
6.14(c) 6.12(c) 6.22(c) 6.75(c) 6.62(c) Last
1 556 646 2 190 782 1 415 958 3 546 742 5 244 733 Volume
-2.23% -0.33% +1.63% +8.52% -1.93% Change
More quotes
Financials (USD)
Sales 2018 18,7 M
EBIT 2018 -137 M
Net income 2018 -142 M
Finance 2018 71,0 M
Yield 2018 -
Sales 2019 117 M
EBIT 2019 -70,6 M
Net income 2019 -75,1 M
Finance 2019 50,5 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 80,6x
EV / Sales2019 13,1x
Capitalization 1 576 M
More Financials
Company
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women.Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and... 
Sector
Pharmaceuticals
Calendar
11/05Earnings Release
More about the company
Surperformance© ratings of TherapeuticsMD Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on THERAPEUTICSMD INC
09/20THERAPEUTICSMD : Announces the FDA has Granted AnnoveraTM Marketing Exclusivity ..
BU
09/13THERAPEUTICSMD : Announces Commercial Availability of Imvexxy™ 4 mcg
BU
09/05THERAPEUTICSMD, INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
08/22THERAPEUTICSMD : to Present at 13th Annual Wells Fargo Securities Healthcare Con..
BU
08/21THERAPEUTICSMD, INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
08/16THERAPEUTICSMD : Announces Closing of its Underwritten Public Offering and Concu..
AQ
08/10THERAPEUTICSMD : Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/..
BU
08/09THERAPEUTICSMD : Announces Proposed $65 Million Underwritten Public Offering and..
AQ
08/09KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Strategic Partnership
AQ
08/09THERAPEUTICSMD : Announces Pricing of Its Underwritten Public Offering and Concu..
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
07:24aASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
09/21JOHNSON & JOHNSON : J&J Unit Agrees To Sell Sterilization Unit for $2.7 Billion
DJ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/21Triple Set of EMA Recommendations for Novartis Drugs
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
02:48aZacks: Analysts Expect TherapeuticsMD Inc $TXMD Will Announce Quarterly Sales.. 
09/22TherapeuticsMD $TXMD Shares Up 8.5%  
09/21TherapeuticsMD $TXMD Upgraded at ValuEngine  
09/20$TXMD: TherapeuticsMD announces that Annovera has been granted marketing excl.. 
09/20$TXMD (+2.4% pre) TherapeuticsMD Announces FDA has Granted Annovera Marketing..
2
More tweets
Qtime:83
News from SeekingAlpha
09/20FDA grants marketing exclusivity as a NCE to TherapeuticsMD's Annovera 
09/10Buy Urban Outfitters On Weakness - Cramer's Lightning Round (9/7/18) 
08/14TherapeuticsMD (TNXXF) FDA Approval Conference Call - Slideshow 
08/13TherapeuticsMD Announces FDA Approval For Year-Round Contraceptive Ring 
08/123 THINGS IN BIOTECH, AUGUST 12 : Sesen's Bladder Cancer Therapy Get Moving 
Chart THERAPEUTICSMD INC
Duration : Period :
TherapeuticsMD Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERAPEUTICSMD INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 15,9 $
Spread / Average Target 135%
EPS Revisions
Managers
NameTitle
Robert G. Finizio Chief Executive Officer & Director
John C. K. Milligan President & Director
Tommy George Thompson Chairman
Jason S. Spitz VP-Operations, Marketing & Commercial Development
Daniel Alan Cartwright Chief Financial Officer, Treasurer & VP
Sector and Competitors
1st jan.Capitalization (M$)
THERAPEUTICSMD INC9.60%1 576
ABBVIE-4.60%140 343
MERCK KGAA-2.89%13 233
KYOWA HAKKO KIRIN CO LTD-6.21%10 668
JAZZ PHARMACEUTICALS PLC21.63%9 929
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD53.61%8 308